Roche Gains FDA Priority Review for Tecentriq sBLA in Stage III dMMR Colon Cancer

Roche's supplemental Biologics License Application for adjuvant Tecentriq (atezolizumab) in stage III dMMR/MSI-H colon cancer has cleared FDA acceptance with a PDUFA date of 9 October 2026, placing regulatory affairs and QA teams at combination biologic-chemotherapy regimens on a defined review clock. The sBLA covers both the intravenous formulation and Tecentriq Hybreza, the subcutaneous co-formulation with hyaluronidase-tqjs, in combination with FOLFOX6 chemotherapy following surgical resection.

The filing is anchored in the phase III Alliance ATOMIC study (NCT02912559), a 712-patient, randomised, open-label trial sponsored by the National Cancer Institute and conducted in partnership with the Alliance for Clinical Trials in Oncology. The primary efficacy signal is a 50% reduction in risk of disease recurrence or death versus FOLFOX6 alone, with 36-month disease-free survival of 86% in the combination arm against 76% in the chemotherapy-only arm. Results were published in The New England Journal of Medicine.

Patient selection in the ATOMIC trial relied on immunohistochemistry-based dMMR determination, specifically the VENTANA MMR RxDx Panel. For regulatory affairs leads, the co-development of a companion diagnostic alongside a biologic-chemotherapy combination adds a layer of analytical validation and labelling coordination that will be closely scrutinised during review. Approximately 15% of colon cancer patients present with dMMR/MSI-H tumours, defining the addressable population and shaping the precision of the proposed indication.

From a manufacturing and quality standpoint, the sBLA encompasses two distinct presentations of atezolizumab: the established IV formulation and the subcutaneous Hybreza co-formulation. Plant heads and QA directors supporting commercial-scale supply should be tracking any process validation commitments tied to the Hybreza presentation, given that subcutaneous biologics carry distinct fill-finish and device compatibility requirements under 21 CFR Part 211 and relevant ICH Q10 quality system expectations.

Roche has indicated parallel regulatory submissions are planned with the European Medicines Agency, extending the compliance and manufacturing readiness timeline beyond the US review cycle. If the FDA approves by the October 2026 PDUFA date, Tecentriq plus FOLFOX6 would represent the first immunotherapy-based adjuvant option for this dMMR/MSI-H population, a designation that carries specific post-approval commitments around pharmacovigilance and, potentially, risk evaluation and mitigation strategies.

The October 2026 PDUFA date sets a concrete checkpoint against which manufacturing scale-up, companion diagnostic alignment, and labelling finalisation must converge.

Source: GlobeNewswire via Roche press release, 11 June 2026.